reference/33831561

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/33831561

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Journal Article\|Observational Study\|Research Support, Non-U.S. Gov't
issn	2045-2322
issueIdentifier	1
pageRange	12336-
publicationName	Scientific Reports
startingPage	12336
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_22bd164e5ad1feb8769f1f4831d22416 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_d813a34c1e4381504d2b075a53f74917 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a0f1180d1103e1ce26769ce9151e6870 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_487baf6554eb36bb22c6138d90a7c50f
bibliographicCitation	Liu S, Jiang C, Yang L, Huang J, Peng R, Wang X, He W, Bai L, Zhou Y, Zhang B, Xia L. First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study. Scientific Reports. 2020 Jul 23;10(1):12336. doi: 10.1038/s41598-020-69230-5.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a00b6b779689607a3aeac853ea0f3cbf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f749cfdca0d90dd1b6d4e4932dc98ecc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c16b09fc7ada4ce50dec18ce549a5f7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d722ce470d2c0dfacd3dd06e004da070 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_11a48ed032cd010ab0f75cc343e5033a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bdde8aec6621981538af431b69ac2f85 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31acb866ca9613feb7e623c630add0ea http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_23c746236d3a0a9490e7c6f1b1ded9c7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_78dd3a3443b82d3b5f8738871bdd63bf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c81078e1ae05f8ceedc20ffcd7908758 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8ba18b043a9b7e5aa6ce8eb9c4d5a064
date	2020-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1038/s41598-020-69230-5 https://pubmed.ncbi.nlm.nih.gov/PMC7378223 https://pubmed.ncbi.nlm.nih.gov/32704062
isPartOf	https://portal.issn.org/resource/ISSN/2045-2322 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/39356
language	English
source	https://www.crossref.org/ https://scigraph.springernature.com/ https://pubmed.ncbi.nlm.nih.gov/
title	First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
discusses	http://id.nlm.nih.gov/mesh/M0422675 http://id.nlm.nih.gov/mesh/M0443627
hasSubjectTerm	http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112 http://purl.org/au-research/vocabulary/anzsrc-for/2008/11
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9672 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603

Total number of triples: 39.